Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asciminib in pediatric and young adults with relapsed or refractory Ph+ or ABL-class Ph-like ALL
NL-OMON61087Phase 2Not yet recruiting
- Sponsor
- Novartis
- Start
- Oct 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of asciminib in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Novartis. Primary endpoints: Incidence of dose-limiting toxicities during cycle 1, Incidence and severity of adverse events and laboratory safety findings during cycle 1 and 1 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
asciminib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NL-OMON61087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61087.